These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28161988)

  • 1. Therapeutic inhibition of BCL-2 and related family members.
    Levy MA; Claxton DF
    Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
    Merino D; Lok SW; Visvader JE; Lindeman GJ
    Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BCL-2-like Proteins to Kill Cancer Cells.
    Cory S; Roberts AW; Colman PM; Adams JM
    Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW; Huang D
    Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
    Adams JM; Cory S
    Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BH3 mimetics: status of the field and new developments.
    Billard C
    Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL-2: Long and winding path from discovery to therapeutic target.
    Schenk RL; Strasser A; Dewson G
    Biochem Biophys Res Commun; 2017 Jan; 482(3):459-469. PubMed ID: 28212732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutics targeting Bcl-2 in hematological malignancies.
    Ruefli-Brasse A; Reed JC
    Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
    Yu L; Liu S
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of BH3 mimetics in myeloid leukemias.
    Parry N; Wheadon H; Copland M
    Cell Death Dis; 2021 Feb; 12(2):222. PubMed ID: 33637708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.
    Opferman JT
    FEBS J; 2016 Jul; 283(14):2661-75. PubMed ID: 26293580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
    Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
    PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
    Vogler M; Walter HS; Dyer MJS
    Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
    Mullard A
    Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
    [No Abstract]   [Full Text] [Related]  

  • 18. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
    Suvarna V; Singh V; Murahari M
    Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.
    Gibson CJ; Davids MS
    Clin Cancer Res; 2015 Nov; 21(22):5021-9. PubMed ID: 26567361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.